CPT-TCO

CPT-TCO,Camptothecin-TCO can be designed for various tumor types by incorporating specific ligands on the drug delivery vehicle that are recognized by receptors overexpressed in particular tumors. This increases the localization of the drug to cancer cells while sparing normal tissues.

The conjugation of camptothecin with TCO allows for the selective targeting of cancer cells. The camptothecin-TCO can remain inactive until it is brought to the site of the tumor and is reacted with a tetrazine (or another Diels-Alder partner), leading to the release of the active drug form. This reduces systemic toxicity and enhances treatment specificity.Utilizing bioorthogonal reactions not only allows for drug delivery but also enables the potential for tracking the distribution and accumulation of the drug within the body using imaging techniques. This dual function can greatly enhance therapeutic efficacy and patient monitoring during cancer treatment.

msds of Camptothecin-TCO